Summary: WIRED investigates the growth of support for psychedelic medicine, highlighting how entrepreneurs from the technology industry are contributing to the field through philanthropic contributions to non-profit organizations such as MAPS and financial investments into emerging for-profit psychedelic pharmaceutical companies. “At the helm of this new pharmaceutical ‘revolution,’ however, is an alliance between traditional psychiatry—including at prestigious research facilities like the Multidisciplinary Association for Psychedelic Studies (MAPS), New York University, and the Johns Hopkins Center for Psychedelic and Consciousness Research— and their financial backers, many of whom come from the world of startups, venture capital, and Big Tech,” explains Kelsey Osgood of WIRED.
